Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Recruiting1
Enrolling By Invitation1
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07219043Phase 2RecruitingPrimary

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

NCT07444489Phase 3Enrolling By Invitation

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

NCT05890430Not Yet Recruiting

Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation

Showing all 3 trials

Research Network

Activity Timeline